However, it is important to note that, especially in today’s cohorts of men with prostate cancer indicated for radical treatment, most patients tend to be classified as stage T1c, i.e., a non-palpable tumor diagnosed because of PSA elevation or other biomarkers. This evidence concerns the gene KLK3 and prostate carcinoma.